54 related articles for article (PubMed ID: 2309110)
1. Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer.
Tsukuda M; Mochimatsu I; Nagahara T; Kokatsu T; Sawaki S; Kubota A; Furkawa M; Arai Y
Cancer Immunol Immunother; 1993; 36(1):52-6. PubMed ID: 8422668
[TBL] [Abstract][Full Text] [Related]
2. Comparing the effects of intravenous and subcutaneous Erythropoietin on blood indices in hemodialysis patients.
Ghasemi F; Abdi A; Salari N; Tohidi MR; Faraji A
Sci Rep; 2019 Feb; 9(1):2284. PubMed ID: 30783118
[TBL] [Abstract][Full Text] [Related]
3. Controversies in selection of epoetin dosages. Issues and answers.
Zachée P
Drugs; 1995 Apr; 49(4):536-47. PubMed ID: 7789287
[TBL] [Abstract][Full Text] [Related]
4. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].
Ruedin P; Stoerman C; Pechère-Bertschi A; Leski M
Nephrologie; 1992; 13(2):87-92. PubMed ID: 1608502
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
Frenken LA; Verberckmoes R; Michielsen P; Koene RA
Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
[TBL] [Abstract][Full Text] [Related]
7. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
Yagil Y
Isr J Med Sci; 1997 Jan; 33(1):36-44. PubMed ID: 9203516
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
[TBL] [Abstract][Full Text] [Related]
10. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous.
Hörl WH
Acta Haematol; 1992; 87 Suppl 1():16-9. PubMed ID: 1574961
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin therapy in patients with chronic renal failure.
Pinevich AJ; Petersen J
West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin and renal anemia.
Hörl WH
Biotechnol Ther; 1991; 2(3-4):213-30. PubMed ID: 1845127
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
